Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

BioSyent records 27% revenue growth in Q1 2026 thanks to Oral Science acquisition

BioSyent reported consolidated revenue of CAD 13.9 million for Q1 2026 (+27% year‑on‑year) and unchanged earnings per share of CAD 0.20. The acquisition of Oral Science contributed about CAD 3.0 million to March 2026 revenue; EBITDA rose to CAD 3.6 million and net income to CAD 2.345 million. The company reaffirmed its guidance (Q2 EPS CAD 0.21, Q3 EPS CAD 0.22), plans international expansion of the Oral Science product line, and warned of ongoing risks such as geopolitical tensions and rising energy costs. » More on de.investing.com
BioSyent misses revenue guidance for Q4 2025, EPS meets expectations

BioSyent reports Q4 2025 earnings per share of CAD 0.17, in line with expectations, while revenue of CAD 9.67 million missed the CAD 10.4 million forecast by 7.02%. The company reported its 62nd consecutive profitable quarter and revenue growth of 10% year over year, supported by acquisitions such as Tibelia and strong international pharmaceutical growth. BioSyent raised the quarterly dividend for 2026 by 10% and signaled continued earnings growth through EPS guidance for 2026; the stock rose slightly in after-hours trading. » More on de.investing.com
BioSyent doubles in size through acquisition of Oral Science despite missing Q4 revenue guidance

BioSyent reports Q4 2025 revenue of CAD 9.7m, missing analyst expectations of CAD 10.4m, but remains profitable with rising EBITDA and net income. The company completed the CAD 25.5m acquisition of Oral Science; Oral Science contributed about CAD 30.9m in revenue in 2025, which pro forma doubles the company’s size. The acquisition will be operated as a standalone oral health division, financed with cash, debt and equity, and BioSyent plans to fully repay the acquisition debt in 2026. Management highlights diversification, cross‑selling potential, a dividend increase and ongoing share buybacks, but notes integration risks and geopolitical headwinds. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, BIOSYENT INC. Aktie has already paid €0.10 in dividends. The last payout was in September.

Financials

In the last quarter, BIOSYENT INC. Aktie had revenue of €12.26m and net profit of €1.76m

(EUR)	June 2026	YoY
Revenue	12.26m	93.17%
Gross profit	7.97m	61.57%
Net profit	1.76m	39.70%
EBITDA	3.07m	65.82%

Fundamentals

Metric	Value
Market capitalization	€122.15m
Number of shares	11.31m
52-week high/low	€11.11 - €6.81
Dividend yield	1.24%
Dividends TTM	€0.13
Beta	0.63
P/E ratio	19.03
PEG ratio	0.93
P/B ratio	4.16
P/S ratio	3.40

Company profile

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.